Treatment of Proliferative Lupus Nephritis—A Critical Approach

摘要: Objectives To discuss the current management of proliferative lupus nephritis (PLN), with a focus on strategies to improve long-term outcome and reduce treatment toxicity while minimizing risk relapse. Methods The literature used in systemic erythematosus (SLE) PLN from 1975 2006, using PubMed National Library Medicine, was reviewed. Results high efficacy standard therapeutic regimen PLN, traditionally associating cyclophosphamide (CYC) corticosteroids (CS), has markedly ameliorated prognosis disease, more than 80% patients achieving complete or partial remission. renal positively influenced general survival rates. Ten-year rates now surpass 75% continue improve. In view improved survival, major aims include preventing organ damage toxicity, which can contribute significantly chronic morbidity mortality lupus. A number high-quality trials have been reported, making us confident value different immunosuppressive protocols, several novel drugs are still under investigation. Conclusion Recent basic clinical research enormously our understanding pathogenesis SLE suggested new, targeted approaches therapy. These therapies expected help next decade.